Imipenem

Generic Name: Imipenem

Brand Names: Primaxin, Recarbrio

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₇N_₃O_₄S

CAS Number: 64221-86-9

Unique Ingredient Identifier: Q20IM7HE75

Background: Imipenem is a semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to many beta-lactamases. Similar compounds include meropenem, known for having greater activity against Gram negative bacteria, and the newer ertapenem which exhibits a longer half-life due to increased binding to plasma proteins. Imipenem is commonly used in combination with cilastatin and is now available in a triple-drug product with cilastatin and relebactam which was recently approved by the FDA. Imipenem was first approved by the FDA in November 1985 as the combination product Primaxin marketed by Merck & Co.

Indication: Imipenem is indicated, in combination with cilastatin with or without relebactam, for the treatment of bacterial infections including respiratory, skin, bone, gynecologic, urinary tract, and intra-abdominal as well as septicemia and endocarditis.

Associated Conditions: Bacterial Septicemia, Bone and Joint Infections, Complicated Intra-Abdominal Infections (cIAIs) caused by Gram-negative Bacteria, Complicated Urinary Tract Infection, Complicated Urinary Tract Infection caused by Gram-negative Bacteria, Endocarditis caused by staphylococcus aureus, Gynecological Infection, Intraabdominal Infections, Lower respiratory tract infection bacterial, Nosocomial Pneumonia caused by Gram-negative Bacteria, Pyelonephritis, Skin and Subcutaneous Tissue Bacterial Infections, Uncomplicated Urinary Tract Infections, Ventilator Associated Bacterial Pneumonia caused by Gram-negative Bacteria

Clinical Trials

A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

Phase 3

Recruiting

Conditions: Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)

Interventions: Drug: HRS-8427
Drug: Imipenem and Cilastatin Sodium
Drug: Imipenem and Cilastatin Sodium placebo
Drug: HRS-8427 placebo

First Posted Date: 2024-08-23

Last Posted Date: 2025-01-22

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 578

Registration Number: NCT06569056

Locations: 🇨🇳
Shanghai Huashan Hospital, Shanghai, Shanghai, China

A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis

Phase 2

Not yet recruiting

Conditions: Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)

Interventions: Drug: Imipenem and Cilastatin Sodium
Drug: HRS -8427

First Posted Date: 2023-11-22

Last Posted Date: 2023-11-22

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 126

Registration Number: NCT06144060

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

Phase 2

Recruiting

Conditions: Pulmonary Disease Due to Mycobacteria (Diagnosis)

Interventions: Drug: Amikacin
Drug: Tigecycline
Drug: Imipenem
Drug: Cefoxitin
Drug: Linezolid
Drug: Azithromycin
Drug: co-trimoxazole
Drug: Clarithromycin
Drug: Clofazimine
Drug: Doxycycline
Drug: Moxifloxacin
Drug: Ethambutol
Drug: Bedaquiline
Drug: Rifabutin

First Posted Date: 2020-03-17

Last Posted Date: 2024-12-11

Lead Sponsor: The University of Queensland

Target Recruit Count: 300

Registration Number: NCT04310930

Locations: 🇦🇺
St George Hospital, Kogarah, New South Wales, Australia
🇦🇺
Austin Hospital, Heidelberg, Victoria, Australia
🇦🇺
Royal Melbourne Hospital, Parkville, Victoria, Australia

and more 47 locations

A Randomized Controlled Trial Comparing Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Management of Spontaneous Bacterial Peritonitis Presenting With Septic Shock.

Not Applicable

Conditions: Spontaneous Bacterial Peritonitis

Interventions: Drug: Imipenem
Drug: Tigecycline
Drug: GMCSF
Drug: Colistin

First Posted Date: 2019-12-23

Last Posted Date: 2021-02-16

Lead Sponsor: Institute of Liver and Biliary Sciences, India

Target Recruit Count: 90

Registration Number: NCT04208763

Locations: 🇮🇳
Institute of Liver and Biliary Sciences, New Delhi, Delhi, India

PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients

Conditions: Critical Illness
Bacterial Infections

Interventions: Drug: Meropenem
Drug: Imipenem

First Posted Date: 2019-02-28

Last Posted Date: 2020-05-01

Lead Sponsor: Prince of Songkla University

Target Recruit Count: 102

Registration Number: NCT03858387

Locations: 🇹🇭
Faculty of Medicine, Prince of Songkla University, Thailand, Hat Yai, Songkla, Thailand

Imipenem in Critically Ill Patients

Phase 4

Conditions: Critically Ill Patients With ECMO

Interventions: Drug: Imipenem

First Posted Date: 2018-12-14

Last Posted Date: 2019-02-15

Lead Sponsor: Prince of Songkla University

Target Recruit Count: 12

Registration Number: NCT03776305

Locations: 🇹🇭
Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkla, Thailand

Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT

Phase 2

Conditions: Antibacterial Prophylaxis
Hematological Malignancies
Allogenetic Hematopoietic Stem Cell Transplantation
Imipenem

Interventions: Drug: Imipenem

First Posted Date: 2018-11-07

Last Posted Date: 2018-11-07

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 250

Registration Number: NCT03733340

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

The Analysis of Factors Influencing the Vd of Imipenem in Septic Shock Patients

Completed

Conditions: Septic Shock

Interventions: Drug: Imipenem

First Posted Date: 2017-10-12

Last Posted Date: 2021-01-05

Lead Sponsor: Southeast University, China

Target Recruit Count: 25

Registration Number: NCT03308214

Locations: 🇨🇳
Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China

Evaluation of Innovative Tools in Development of Antibiotics

Phase 1

Completed

Conditions: Pneumonia

Interventions: Drug: Ciprofloxacin
Drug: Imipenem

First Posted Date: 2017-06-06

Last Posted Date: 2021-09-01

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 10

Registration Number: NCT03177720

Locations: 🇦🇹
Medical University of Vienna, Vienna, Austria

Efficacy of Betalactam Antibiotics in Prolonged Infusion Compared to Intermittent in Pediatric Patients With Sepsis

Not Applicable

Completed

Conditions: Sepsis

Interventions: Drug: Continuous Piperacillin/tazobactam
Drug: Intermittent Piperacillin/tazobactam
Drug: Intermittent Imipenem
Drug: Intermittent Meropenem
Drug: Extended Meropenem
Drug: Extended Imipenem

First Posted Date: 2017-01-13

Last Posted Date: 2021-08-05

Lead Sponsor: Coordinación de Investigación en Salud, Mexico

Target Recruit Count: 426

Registration Number: NCT03019965

Locations: 🇲🇽
Hospital Infantil de México Federico Gómez, Mexico, Distrito Federal, Mexico
🇲🇽
Instituto Mexicano del Seguro Social, Mexico, Distrito Federal, Mexico

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy